You need to be logged in to view this video

Innovative Pharmaceutical Cannabidiol (CBD) Therapies for Heart Disease

Released on Wednesday, June 10, 2020•BIOTECH

Share
Facebook Twitter LinkedIn SMS

David Elsley, president and CEO, provides a corporate presentation on how Cardiol Therapeutics (TSX:CRDL) is focused on producing pharmaceutical cannabidiol (CBD) products and developing innovative therapies for heart diseases, including acute myocarditis and other causes of heart failure. The Company's lead product, CardiolRx™, is formulated to be the most consistent cannabidiol formulation on the market. CardiolRx— is pharmaceutically produced, manufactured under cGMP, and is THC free (<5 ppm). The Company also plans to commercialize CardiolRx— in the billion-dollar market for medicinal cannabinoids in Canada and is pursuing distribution opportunities in Europe and Latin America.

David Elsley

Cardiol Therapeutics, President and CEO

David Elsley, president and CEO of Cardiol Therapeutics, has more than 25 years of experience developing, financing, and managing all aspects of corporate development of biotechnology and high-growth organizations. He is also the founder and former president and CEO of Vasogen, Inc.